يعرض 1 - 10 نتائج من 86 نتيجة بحث عن '"MESH : Paraproteinemias"', وقت الاستعلام: 0.71s تنقيح النتائج
  1. 1

    المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Fédération Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG) Institut National Du Cancer, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie

    المصدر: American Journal of Hematology
    American Journal of Hematology, 2023, 98 (2), pp.264-271. ⟨10.1002/ajh.26785⟩
    American journal of hematology, Vol. 98, no.2, p. 264-271 (2023)

    الوصف: International audience; Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained. In order to identify genetic factors predisposing to familial monoclonal gammopathy, the Intergroupe Francophone du Myélome identified 318 families with at least two confirmed cases of monoclonal gammopathy. There were 169 families with parent/child pairs and 164 families with cases in at least two siblings, compatible with an autosomal transmission. These familial cases were compared with sporadic cases who were matched for age at diagnosis, sex and immunoglobulin isotype, with 10 sporadic cases for each familial case. The gender distribution, age and immunoglobulin subtypes of familial cases were unremarkable in comparison to sporadic cases. With a median follow-up of 7.4 years after diagnosis, the percentage of MGUS cases having evolved to MM was 3%. The median overall survival of the 148 familial MM cases was longer than that of matched sporadic cases, with projected values of 7.6 and 16.1 years in patients older and younger than 65 years, respectively. These data suggest that familial cases of monoclonal gammopathy are similar to sporadic cases in terms of clinical presentation and carry a better prognosis.

  2. 2
    دورية أكاديمية

    المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang Rennes (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Fédération Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG) Institut National Du Cancer

    المصدر: ISSN: 0361-8609.

    الوصف: International audience ; Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained. In order to identify genetic factors predisposing to familial monoclonal gammopathy, the Intergroupe Francophone du Myélome identified 318 families with at least two confirmed cases of monoclonal gammopathy. There were 169 families with parent/child pairs and 164 families with cases in at least two siblings, compatible with an autosomal transmission. These familial cases were compared with sporadic cases who were matched for age at diagnosis, sex and immunoglobulin isotype, with 10 sporadic cases for each familial case. The gender distribution, age and immunoglobulin subtypes of familial cases were unremarkable in comparison to sporadic cases. With a median follow-up of 7.4 years after diagnosis, the percentage of MGUS cases having evolved to MM was 3%. The median overall survival of the 148 familial MM cases was longer than that of matched sporadic cases, with projected values of 7.6 and 16.1 years in patients older and younger than 65 years, respectively. These data suggest that familial cases of monoclonal gammopathy are similar to sporadic cases in terms of clinical presentation and carry a better prognosis.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36588407; hal-03980698; https://univ-rennes.hal.science/hal-03980698Test; PUBMED: 36588407

  3. 3
    دورية أكاديمية

    المساهمون: Service de Néphrologie et Immunologie Clinique CHU de Nantes, Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Institut de Transplantation et de Recherche en Transplantation CHU Nantes (ITERT), Hôtel-Dieu de Nantes, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service d'Hématologie Clinique Nantes (Unité d'Investigation Clinique), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)

    المصدر: ISSN: 1121-8428.

    الوصف: International audience

    العلاقة: hal-04261587; https://hal.science/hal-04261587Test

  4. 4
    رسالة جامعية

    المؤلفون: Burns, Robert Edward

    المساهمون: UFR Médecine Santé - Université Paris Cité (UFR Médecine UPCité), Université Paris Cité (UPCité), Sébastien Mule

    المصدر: https://dumas.ccsd.cnrs.fr/dumas-03637708Test ; Médecine humaine et pathologie. 2020.

    الوصف: Purpose: PET/MRI can provide simultaneous whole-body (WB) acquisition of T1,T2DIXON, Diffusion Weighted Images (DWI), Dynamic Contrast-Enhanced (DCE), and FDG-PET sequences. The objective of this study was to assess and compare the diagnostic performance of 4 combinations of these sequences for baseline staging of patients with monoclonal gammopathies (MG). Materials and methods: 104 patients with MG were included in this IRB approved study. Readers reviewed initial PET/MRIs for the presence of focal lesions (FL) and bone marrow infiltration (BMI) using 4 different image datasets: WB-MRI (including DWI), 3DT1-PET, WB-PET/MRI and WB-DCE-PET/MRI. A reference standard was established by a panel review of all baseline and follow-up imaging, biological and pathological data. The diagnostic performance for each image dataset to detect FL and BMI were evaluated and compared (Fisher’s exact test). Results: The sensitivity, specificity and accuracy for FL of WB-MRI was 87, 97 and 92%; of 3DT1-PET was 78, 97, and 95%; of WB-PET-MRI was 93, 97, and 95%; WB-DCE-PET-MRI was 93, 97, and 95%. The sensitivity of WB-PET-MRI and WB-DCE-PET-MRI were superior to 3DT1-PET (p=0,036) without decreasing specificity. The sensitivity, specificity and accuracy of WB-MRI for BMI was 91, 80 and 85% ; of 3DT1-PET was 53, 89, and 74% ; of WB-PET-MRI was 98, 66, and 79% ; of WB-DCE-PET-MRI was 98, 59, and 75%. 3DT1-PET lacked sensitivity compared to all other datasets (p<0.0001). WB-MRI had better sensitivity than 3DT1-PET (p<0.001) and specificity than DCE-PET/MRI (p<0.001). Conclusion: PET/MRI should combine both WB bone marrow dedicated MRI and FDG PET images with no added value of DCE for baseline staging. ; L’objectif de cette étude était d'évaluer et de comparer les performances diagnostiques de 4 combinaisons de séquences en TEP/IRM pour le bilan initial des patients atteints de gammapathies monoclonales (GM). Matériel et Méthodes :104 patients avec une GM ont été inclus dans cette étude approuvée par l'IRB. Les lecteurs ont ...

  5. 5
    دورية أكاديمية

    المساهمون: CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pneumologie B, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service d'anatomie pathologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu, Département de pathologie Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'anatomo-pathologie CHU HEGP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service d'immunologie biologique, Service de pneumologie Hôpital Foch, Hôpital Foch Suresnes

    المصدر: ISSN: 0006-4971.

    الوصف: International audience ; We have recently described a new form of light chain deposition disease (LCDD) presenting as a severe cystic lung disorder requiring lung transplantation. There was no bone marrow plasma cell proliferation. Because of the absence of disease recurrence after bilateral lung transplantation and of serum-free light chain ratio normalization after the procedure, we hypothesized that monoclonal light chain synthesis occurred within the lung. The aim of this study was to look for the monoclonal B-cell component in 3 patients with cystic lung LCDD. Histologic examination of the explanted lungs showed diffuse nonamyloid kappa light chain deposits associated with a mild lymphoid infiltrate composed of aggregates of small CD20(+), CD5(-), CD10(-) B lymphocytes reminiscent of bronchus-associated lymphoid tissue. Using polymerase chain reaction (PCR), we identified a dominant B-cell clone in the lung in the 3 studied patients. The clonal expansion of each patient shared an unmutated antigen receptor variable region sequence characterized by the use of IGHV4-34 and IGKV1 subgroups with heavy and light chain CDR3 sequences of more than 80% amino acid identity, a feature evocative of an antigen-driven process. Combined with clinical and biologic data, our results strongly argue for a new antigen-driven primary pulmonary lymphoproliferative disorder.

  6. 6
    دورية أكاديمية

    المساهمون: Université Claude Bernard Lyon 1 - Institut des Sciences Pharmaceutiques et Biologiques (UCBL ISPB), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Evaluation et modélisation des effets thérapeutiques LBBE, Département biostatistiques et modélisation pour la santé et l'environnement LBBE, Université de Lyon-Université de Lyon-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon

    المصدر: ISSN: 0003-3928.

    الوصف: International audience ; Beta-blockers are widely prescribed in elderly patients and may induce severe adverse drug reactions. We report a case of bisoprolol-induced bradycardia in an elderly patient with impaired renal function and use of cytochrome P450 inhibitors. A literature review has been performed in order to analyze pharmacokinetic risk factors of beta-blockers overdosing in geriatrics. Various mechanisms can result in decreased elimination of beta-blockers. These mechanisms vary according to the beta-blocker agent and may be combined in some individuals, especially elderly patients. This can lead to unexpected overexposure. Knowledge about drug interactions and pharmacokinetic elimination pathways is important for preventing overexposure and adverse drug reactions when using beta-blockers.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29544975; hal-04627209; https://hal.science/hal-04627209Test; PUBMED: 29544975

  7. 7
    دورية أكاديمية

    المساهمون: Universität Zürich Zürich = University of Zurich (UZH), Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Des Maladies Rénales Rares aux Maladies Fréquentes, Remodelage et Réparation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie )

    المصدر: ISSN: 1046-6673.

    الوصف: International audience ; Monoclonal gammopathies are frequently complicated by kidney lesions that increase the disease morbidity and mortality. In particular, abnormal Ig free light chains (LCs) may accumulate within epithelial cells, causing proximal tubule (PT) dysfunction and renal Fanconi syndrome (RFS). To investigate the mechanisms linking LC accumulation and PT dysfunction, we used transgenic mice overexpressing human control or RFS-associated κ LCs (RFS- κ LCs) and primary cultures of mouse PT cells exposed to low doses of corresponding human κ LCs (25 μ g/ml). Before the onset of renal failure, mice overexpressing RFS- κ LCs showed PT dysfunction related to loss of apical transporters and receptors and increased PT cell proliferation rates associated with lysosomal accumulation of κ LCs. Exposure of PT cells to RFS- κ LCs resulted in κ LC accumulation within enlarged and dysfunctional lysosomes, alteration of cellular dynamics, defective proteolysis and hydrolase maturation, and impaired lysosomal acidification. These changes were specific to the RFS- κ LC variable (V) sequence, because they did not occur with control LCs or the same RFS- κ LC carrying a single substitution (Ala30→Ser) in the V domain. The lysosomal alterations induced by RFS- κ LCs were reflected in increased cell proliferation, decreased apical expression of endocytic receptors, and defective endocytosis. These results reveal that specific κ LCs accumulate within lysosomes, altering lysosome dynamics and proteolytic function through defective acidification, thereby causing dedifferentiation and loss of reabsorptive capacity of PT cells. The characterization of these early events, which are similar to those encountered in congenital lysosomal disorders, provides a basis for the reported differential LC toxicity and new perspectives on LC-induced RFS.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26614382; hal-02364437; https://hal.science/hal-02364437Test; PUBMED: 26614382; PUBMEDCENTRAL: PMC4926980

  8. 8

    المساهمون: Service de Neurologie [CHU Limoges], CHU Limoges, Biomolécules Thérapies anti-tumorales (EA4021), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Centre de référence national neuropathies périphériques rares [CHU Limoges]

    المصدر: Current Opinion in Critical Care
    Current Opinion in Critical Care, Lippincott, Williams & Wilkins, 2011, 17 (2), pp.101-5. ⟨10.1097/MCC.0b013e328342aded⟩

    الوصف: International audience; PURPOSE OF REVIEW: Immune-mediated neuropathies are increasingly recognized as potential causes of disability. Their diagnostic criteria and management options are still a matter of debate. This review focuses on recent findings in the diagnostic and therapeutic management of these disorders and on their prognostic factors. RECENT FINDINGS: The more widespread use of consensus criteria has improved diagnostic strategies for immune-mediated neuropathies. Studies of large prospective series have defined the spectrum of these disorders and their respective prognoses. Although treatment of these disorders mostly relies on corticosteroids and intravenous immunoglobulin, recent controlled trials have indicated the value of targeted immunotherapies. The further development of these therapies requires better understanding of the pathophysiology of these disorders. Immunological and immunopathological studies have improved our understanding of immune-mediated neuropathies over the last few years. SUMMARY: Identifying immune-mediated neuropathies is important, as these disorders are treatable. Diagnostic strategies have improved our capacity to recognize affected patients who can be offered effective treatments. Therapeutic options for immune-mediated neuropathies are still rather limited, although targeted immunotherapies may improve the prognosis of these disorders in the near future.

  9. 9

    المؤلفون: Laurent Magy, Jean-Michel Vallat

    المساهمون: Service de Neurologie [CHU Limoges], CHU Limoges, Biomolécules Thérapies anti-tumorales (EA4021), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)

    المصدر: Expert Opinion on Pharmacotherapy
    Expert Opinion on Pharmacotherapy, Taylor & Francis, 2009, 10 (11), pp.1741-54. ⟨10.1517/14656560903036095⟩

    مصطلحات موضوعية: Pathology, MESH: Immunotherapy, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, medicine.medical_treatment, Paraproteinemias, MESH: Antibodies, Monoclonal, law.invention, MESH: Paraproteinemias, 0302 clinical medicine, Randomized controlled trial, law, MESH: Motor Neuron Disease, MESH: Animals, Pharmacology (medical), Randomized Controlled Trials as Topic, 0303 health sciences, Antibodies, Monoclonal, Peripheral Nervous System Diseases, General Medicine, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 3. Good health, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Immunotherapy, MESH: Immunosuppressive Agents, MESH: Peripheral Nervous System Diseases, Immunosuppressive Agents, medicine.medical_specialty, Evidence-based practice, medicine.drug_class, Monoclonal antibody, 03 medical and health sciences, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], medicine, Animals, Humans, Motor Neuron Disease, Adverse effect, 030304 developmental biology, Pharmacology, MESH: Humans, business.industry, MESH: Chronic Disease, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Polyradiculoneuropathy, medicine.disease, Dermatology, MESH: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, MESH: Randomized Controlled Trials as Topic, Peripheral neuropathy, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Chronic Disease, business, 030217 neurology & neurosurgery, Multifocal motor neuropathy

    الوصف: International audience; Immune-mediated neuropathies are treatable disorders that can result in considerable disability in some cases. Chronic immune-mediated neuropathies include chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy and neuropathy associated with monoclonal gammopathy. In recent years, therapeutic strategies for these disorders have become clearer as a result of large, randomized controlled trials. However, the treatments used can have serious adverse effects and at least 30% of patients do not respond to conventional therapies. The aim of this paper is to review available data on evidence-based immunotherapy of chronic immune-mediated neuropathies and to summarize recent findings and results obtained with new innovative therapies, such as new immunosuppressants and monoclonal antibodies.

  10. 10

    المساهمون: Service d'anatomie pathologique [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service de pneumologie B, Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Service d'anatomie pathologique, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôtel-Dieu, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Service d'anatomo-pathologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Service d'immunologie biologique, Service de pneumologie, Hôpital Foch [Suresnes]

    المصدر: Blood
    Blood, American Society of Hematology, 2008, 112 (5), pp.2004-12. 〈10.1182/blood-2007-11-123596〉

    الوصف: We have recently described a new form of light chain deposition disease (LCDD) presenting as a severe cystic lung disorder requiring lung transplantation. There was no bone marrow plasma cell proliferation. Because of the absence of disease recurrence after bilateral lung transplantation and of serum-free light chain ratio normalization after the procedure, we hypothesized that monoclonal light chain synthesis occurred within the lung. The aim of this study was to look for the monoclonal B-cell component in 3 patients with cystic lung LCDD. Histologic examination of the explanted lungs showed diffuse nonamyloid κ light chain deposits associated with a mild lymphoid infiltrate composed of aggregates of small CD20+, CD5−, CD10− B lymphocytes reminiscent of bronchus-associated lymphoid tissue. Using polymerase chain reaction (PCR), we identified a dominant B-cell clone in the lung in the 3 studied patients. The clonal expansion of each patient shared an unmutated antigen receptor variable region sequence characterized by the use of IGHV4-34 and IGKV1 subgroups with heavy and light chain CDR3 sequences of more than 80% amino acid identity, a feature evocative of an antigen-driven process. Combined with clinical and biologic data, our results strongly argue for a new antigen-driven primary pulmonary lymphoproliferative disorder.